Extracellular vesicles: biology and emerging therapeutic opportunities

By S. E. Andaloussi, Imre Mäger, X. Breakefield, M. Wood. Nature reviews. Drug discovery, 2013

3,151 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/fee22610251c2119fb91864628a321522515dd65

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Molly M. Stevens

In Cancer Research

1. C. Théry
2. Asfar S. Azmi
3. Fazlul H. Sarkar
4. Bin Bao
5. Richard J. Simpson
6. H. Ji
7. A. Llorente
8. M. Wood

In Molecular Biology

1. C. Théry
2. Richard J. Simpson
3. Asfar S. Azmi
4. Fazlul H. Sarkar
5. Bin Bao
6. A. Llorente
7. M. Wood
8. P. Vader

Citations in the corpus

• Optimized exosome isolation protocol for cell culture supernatant and human plasma (2015, background): “EVs are capable of inducing local and systemic changes, thereby promoting disease progression in a number of settings (3).”
• Cells release subpopulations of exosomes with distinct molecular and biological properties (2016, methodology): “To understand the potential functional differences between the proteins identified in the distinct vesicle subpopulations, we performed GO enrichment analysis using 4 different protein lists: (1) the full list of all identified proteins across EV populations, and (2) MV, (3) LD-Exo and (4) HD-Exo pr”
• The exosome journey: from biogenesis to uptake and intracellular signalling (2021, neutral): “References [21, 25, 28, 185, 186] [5, 21, 22, 25, 185, 186] [21, 23–26]”
• Lipids in exosomes: Current knowledge and the way forward. (2017, background): “and secreted to the extracellular environment? What is their specific composition? Which physiological and pathological roles do they have? Can exosomes be used as biomarkers or as vehicles for drug delivery? These aspects have been reviewed in several articles during the last years [1,2,7-12].”
• Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, background): “Potential advantages of EV-based drug delivery over the existing synthetic delivery systems (such as liposomes) include decreased immunogenicity and toxicity, increased stability in circulation and tissue, and intrinsic homing abilities (221).”
• A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods. (2015, background): “the form of small RNAs, mRNAs, bioactive lipids, and proteins [1–3].”